Conventional, Complementary and Alternative Medicines: Mechanistic Insights into Therapeutic Landscape of Chronic Obstructive Pulmonary Disease

References

• Pride NB, Vermeire PJERM. Definition and differential diagnosis. Eur Respir Monograph. 1998;3(7):2–5.
   Google Scholar
• Silverman EK. Genetics of COPD. Annu Rev Physiol. 2020;82:413–431.
   PubMed Web of Science ®Google Scholar
• GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585–596.
   PubMed Web of Science ®Google Scholar
• Joppa P, Tkacova R, Franssen FM, et al. Sarcopenic obesity, functional outcomes, and systemic inflammation in patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2016;17(8):712–718.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Arch Bronconeumol. 2014;50(Suppl 1):1–16.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci. 2017;131(13):1541–1558.
   PubMed Web of Science ®Google Scholar
• Pouwels SD, Heijink IH, ten Hacken NH, et al. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol. 2014;7(2):215–226.
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–2365.
   PubMed Web of Science ®Google Scholar
• Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014;20(2):159–166.
   PubMed Web of Science ®Google Scholar
• Cait A, Hughes MR, Antignano F, et al. Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids. Mucosal Immunol. 2018;11(3):785–795. doi:10.1038/mi.2017.75
   PubMed Web of Science ®Google Scholar
• Roduit C, Frei R, Ferstl R, et al. High levels of butyrate and propionate in early life are associated with protection against atopy. Allergy. 2019;74(4):799–809.
   PubMedGoogle Scholar
• Biedermann L, Zeitz J, Mwinyi J, et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One. 2013;8(3):e59260.
   PubMed Web of Science ®Google Scholar
• Bowerman KL, Rehman SF, Vaughan A, et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun. 2020;11(1):5886.
   PubMed Web of Science ®Google Scholar
• Lai HC, Lin TL, Chen TW, et al. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide. Gut. 2022;71(2):309–321.
   PubMedGoogle Scholar
• Chiu YC, Lee SW, Liu CW, et al. Comprehensive profiling of the gut microbiota in patients with chronic obstructive pulmonary disease of varying severity. PLoS One. 2021;16(4):e0249944.
   PubMedGoogle Scholar
• Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3341–3348.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence exacerbates pulmonary inflammation in patients with chronic obstructive pulmonary disease. Respiration. 2010;80(1):59–70.
   PubMedGoogle Scholar
• Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J. 2008;31(1):62–69.
   PubMed Web of Science ®Google Scholar
• Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D. Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur Respir J. 2013;42(1):28–41.
   PubMed Web of Science ®Google Scholar
• Vallese D, Ricciardolo FL, Gnemmi I, et al. Phospho-p38 MAPK expression in COPD patients and asthmatics and in challenged bronchial epithelium. Respiration. 2015;89(4):329–342.
   PubMedGoogle Scholar
• Maunders H, Patwardhan S, Phillips J, Clack A, Richter A. Human bronchial epithelial cell transcriptome: gene expression changes following acute exposure to whole cigarette smoke in vitro. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1248–L1256.
   PubMed Web of Science ®Google Scholar
• Moradi S, Jarrahi E, Ahmadi A, et al. PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy. J Pathol. 2021;254(5):505–518.
   PubMed Web of Science ®Google Scholar
• Malhotra D, Thimmulappa R, Navas-Acien A, et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med. 2008;178(6):592–604.
   PubMed Web of Science ®Google Scholar
• Hwang JW, Rajendrasozhan S, Yao H, et al. FOXO3 deficiency leads to increased susceptibility to cigarette smoke-induced inflammation, airspace enlargement, and chronic obstructive pulmonary disease. J Immunol. 2011;187(2):987–998.
   PubMed Web of Science ®Google Scholar
• Lee J, Jang J, Park SM, Yang SR. An update on the role of Nrf2 in respiratory disease: molecular mechanisms and therapeutic approaches. Int J Mol Sci. 2021;22(16):8406.
   PubMedGoogle Scholar
• Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox Biol. 2020;33:101544.
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Caramori G, Oates T, et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J. 2002;20(3):556–563.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol. 2009;71:451–464.
   PubMed Web of Science ®Google Scholar
• Li J, Ye Z. The potential role and regulatory mechanisms of MUC5AC in chronic obstructive pulmonary disease. Molecules. 2020;25:19.
   Google Scholar
• Zhang XY, Li W, Zhang JR, Li CY, Zhang J, Lv XJ. Roles of sirtuin family members in chronic obstructive pulmonary disease. Respir Res. 2022;23(1):66.
   PubMedGoogle Scholar
• Birch J, Barnes PJ, Passos JF. Mitochondria, telomeres and cell senescence: implications for lung ageing and disease. Pharmacol Ther. 2018;183:34–49.
   PubMed Web of Science ®Google Scholar
• Manzel LJ, Shi L, O’Shaughnessy PT, Thorne PS, Look DC. Inhibition by cigarette smoke of nuclear factor-κB-dependent response to bacteria in the airway. Am J Respir Cell Mol Biol. 2011;44(2):155–165.
   PubMedGoogle Scholar
• Chin CL, Manzel LJ, Lehman EE, et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med. 2005;172(1):85–91.
   PubMedGoogle Scholar
• Shuto T, Xu H, Wang B, et al. Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci USA. 2001;98(15):8774–8779.
   PubMed Web of Science ®Google Scholar
• Manzel LJ, Chin CL, Behlke MA, Look DC. Regulation of bacteria-induced intercellular adhesion molecule-1 by CCAAT/enhancer binding proteins. Am J Respir Cell Mol Biol. 2009;40(2):200–210.
   PubMed Web of Science ®Google Scholar
• Turino GM. Emphysema in COPD: consequences and causes. Thorax. 2006;61(12):1031–1032.
   PubMedGoogle Scholar
• Gharib SA, Manicone AM, Parks WC. Matrix metalloproteinases in emphysema. Matrix Biol. 2018;73:34–51.
   PubMed Web of Science ®Google Scholar
• Heinz A. Elastases and elastokines: elastin degradation and its significance in health and disease. Crit Rev Biochem Mol Biol. 2020;55(3):252–273.
   PubMedGoogle Scholar
• Houghton AM, Quintero PA, Perkins DL, et al. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest. 2006;116(3):753–759.
   PubMed Web of Science ®Google Scholar
• Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1635–1639.
   PubMed Web of Science ®Google Scholar
• Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA, Warner JA. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 2005;6(1):151.
   PubMedGoogle Scholar
• Jones RL, Noble PB, Elliot JG, James AL. Airway remodelling in COPD: it’s not asthma! Respirology. 2016;21(8):1347–1356.
   PubMed Web of Science ®Google Scholar
• Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4–27.
   PubMed Web of Science ®Google Scholar
• Ma J, Rubin BK, Voynow JA. Mucins, mucus, and goblet cells. Chest. 2018;154(1):169–176.
   PubMed Web of Science ®Google Scholar
• Zhou-Suckow Z, Duerr J, Hagner M, Agrawal R, Mall MA. Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. Cell Tissue Res. 2017;367(3):537–550.
   PubMedGoogle Scholar
• Strange C. Alpha-1 antitrypsin deficiency associated COPD. Clin Chest Med. 2020;41(3):339–345.
   PubMedGoogle Scholar
• Olivieri D, Chetta A. Therapeutic perspectives in vascular remodeling in asthma and chronic obstructive pulmonary disease. Chem Immunol Allergy. 2014;99:216–225.
   PubMedGoogle Scholar
• Leung JM, Tiew PY, Mac Aogáin M, et al. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respirology. 2017;22(4):634–650.
   PubMed Web of Science ®Google Scholar
• Bagdonas E, Raudoniute J, Bruzauskaite I, Aldonyte R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:995–1013.
   PubMed Web of Science ®Google Scholar
• Bhat TA, Panzica L, Kalathil SG, Thanavala Y. Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2015;12(Suppl2):S169–175.
   PubMedGoogle Scholar
• Hikichi M, Mizumura K, Maruoka S, Gon Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. J Thorac Dis. 2019;11(Suppl 17):S2129–s2140.
   PubMedGoogle Scholar
• Billington CK, Ojo OO, Penn RB, Ito S. cAMP regulation of airway smooth muscle function. Pulm Pharmacol Ther. 2013;26(1):112–120.
   PubMedGoogle Scholar
• Cazzola M, Page CP, Rogliani P, Matera MG. β2-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187(7):690–696.
   PubMed Web of Science ®Google Scholar
• Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol. 2015;8(4):479–501.
   PubMed Web of Science ®Google Scholar
• Al-Faqawi M, Abuowda Y, Elmassry AE, Böttcher B. Management of chronic obstructive pulmonary disease exacerbations at the Nasser medical complex: a clinical audit. Lancet. 2018;391(Suppl 2):S5.
   PubMedGoogle Scholar
• Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;2006(3):CD006101.
   PubMedGoogle Scholar
• Donner CF, Virchow JC, Lusuardi M. Pharmacoeconomics in COPD and inappropriateness of diagnostics, management and treatment. Respir Med. 2011;105(6):828–837.
   PubMedGoogle Scholar
• Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–533.
   PubMed Web of Science ®Google Scholar
• Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53–67.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–694.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:81–90.
   PubMed Web of Science ®Google Scholar
• Qiu S, Zhong X. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2017;11(3):147–155.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451–461.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019;20(1):104.
   PubMedGoogle Scholar
• Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2012;156(2):105–114.
   PubMed Web of Science ®Google Scholar
• Kuniaki H, Akihiko T, Tetsuya H, et al. Improvement in Frailty in a Patient With Severe Chronic Obstructive Pulmonary Disease After Ninjin’yoeito Therapy: a Case Report. Front Nutr. 2018;5:71.
   PubMedGoogle Scholar
• Hirai K, Homma T, Matsunaga T, et al. Usefulness of Ninjin’yoeito for chronic obstructive pulmonary disease patients with frailty. J Altern Complement Med. 2020;26(8):750–757.
   PubMedGoogle Scholar
• Mukaida K, Hattori N, Kondo K, et al. A pilot study of the multiherb Kampo medicine bakumondoto for cough in patients with chronic obstructive pulmonary disease. Phytomedicine. 2011;18(8–9):625–629.
   PubMedGoogle Scholar
• Sasatani Y, Okauchi S, Ohara G, Kagohashi K, Satoh H. Long-term maintenance of nutritional status with ninjinyoueito in terminal patients with chronic respiratory disease: two case reports. Biomed Rep. 2020;12(3):121–124.
   PubMedGoogle Scholar
• Jo T, Michihata N, Yamana H, et al. Reduction in exacerbation of COPD in patients of advanced age using the Japanese Kampo medicine Dai-kenchu-to: a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:129–139.
   PubMed Web of Science ®Google Scholar
• Li J. International clinical practice guideline of Chinese medicine: chronic obstructive pulmonary disease. World J Tradit Chin Med. 2020;6(1):39–50.
   Google Scholar
• Li SY, Li JS, Wang MH, et al. Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study. BMC Complement Altern Med. 2012;12:197.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang H, Ruan H, et al. Effects of Chinese herbal medicine on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis. 2020;15:2901–2912.
   PubMed Web of Science ®Google Scholar
• Li Y, Tian YG, Li JS, et al. Bufei Yishen granules combined with acupoint sticking therapy suppress oxidative stress in chronic obstructive pulmonary disease rats: Via regulating peroxisome proliferator-activated receptor-gamma signaling. J Ethnopharmacol. 2016;(193):354–361.
   PubMedGoogle Scholar
• Li JS, Zhao P, Yang, LP, et al. System biology analysis of longterm effect and mechanism of Bufei Yishen on COPD revealed by system pharmacology and 3-omics profiling. Sci Rep. 2016;6:25492.
   PubMed Web of Science ®Google Scholar
• Zhao P, Li JS, Li Y, et al. Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2633–2656.
   PubMed Web of Science ®Google Scholar
• Li JS, Wang HF. 基于慢性阻塞性肺疾病急性加重危险窗的袪邪扶正序贯辨证治疗策略. [Sequential syndrome differentiation by eliminating pathogen and strengthening vital Qi on the basis of acute exacerbation of chronic obstructive pulmonary disease risk window]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011;31(9):1276–1280. Chinese.
   PubMedGoogle Scholar
• Jiansheng L, Haifeng W, Suyun L, et al. Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window. Complement Ther Med. 2016;29:109–115.
   PubMedGoogle Scholar
• Haifeng W, Jiansheng L, Suyun L, et al. Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and “AECOPD Risk-Window”: study protocol for a randomized placebo-controlled trial. Trials. 2012;13:40.
   PubMedGoogle Scholar
• Zhao P, Li J, Tian Y, et al. Restoring Th17/Treg balance via modulation of STAT3 and STAT5 activation contributes to the amelioration of chronic obstructive pulmonary disease by Bufei Yishen formula. J Ethnopharmacol. 2018;217:152–162.
   PubMed Web of Science ®Google Scholar
• Qin YQ, Chen YL, Zhao P et al, et al. Tiaobu Feishen therapy inhibits inflammation induced by cigarette smoke extracts in a human monocyte/macrophage cell line. J Tradit Chin Med. 2021;4(3) :360–366.
   Google Scholar
• Chen Y et al . (2019). Three Tiaobu Feishen therapies protect human alveolar epithelial cells against cigarette smoking and tumor necrosis factor--induced inflammation by nuclear factor-kappa B pathway. J Tradit Chin Med, 39(1), 45–49.
   PubMedGoogle Scholar
• Li J, Liu X, Dong H, Zheng W, Feng S, Tian Y, Zhao P, Ma J, Ren Z, Xie Y. (2020). Effective-constituent compatibility-based analysis of Bufei Yishen formula, a traditional herbal compound as an effective treatment for chronic obstructive pulmonary disease. J Integr Med, 18(4), 351–362. 10.1016/j.joim.2020.04.004
   PubMedGoogle Scholar
• Li J, Wang J, Li Y, Zhao P, Tian Y, Liu X, He H, Jia R. (2021). Effective-component compatibility of Bufei Yishen formula protects COPD rats against PM2.5-induced oxidative stress via miR-155/FOXO3a pathway. Ecotoxicol Environ Saf, 228 112918 10.1016/j.ecoenv.2021.112918
   PubMed Web of Science ®Google Scholar
• Li J, Xie Y, Zhao P, et al. A Chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38. Phytomedicine. 2021;83:153475.
   PubMedGoogle Scholar
• Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018;52(5):1801074.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of AQX-1125 in unstable COPD (FLAGSHIP); 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT01954628. Accessed August 12, 2022.
   Google Scholar
• Chun P. Role of sirtuins in chronic obstructive pulmonary disease. Arch Pharm Res. 2015;38(1):1–10.
   PubMedGoogle Scholar
• Mei D, Tan WSD, Tay Y, Mukhopadhyay A, Wong WSF. Therapeutic RNA strategies for chronic obstructive pulmonary disease. Trends Pharmacol Sci. 2020;41(7):475–486.
   PubMed Web of Science ®Google Scholar
• Dong J, Liao W, Tan LH, Yong A, Peh WY, Wong WSF. Gene silencing of receptor-interacting protein 2 protects against cigarette smoke-induced acute lung injury. Pharmacol Res. 2019;139:560–568.
   PubMed Web of Science ®Google Scholar
• Yu Q, Yang D, Chen X, Chen Q. CD147 increases mucus secretion induced by cigarette smoke in COPD. BMC Pulm Med. 2019;19(1):29.
   PubMedGoogle Scholar
• Tam A, Hughes M, McNagny KM, et al. Hedgehog signaling in the airway epithelium of patients with chronic obstructive pulmonary disease. Sci Rep. 2019;9(1):3353.
   PubMedGoogle Scholar
• Wang H, Yao H, Yi B, et al. MicroRNA-638 inhibits human airway smooth muscle cell proliferation and migration through targeting cyclin D1 and NOR1. J Cell Physiol. 2018;234(1):369–381.
   PubMed Web of Science ®Google Scholar
• Zhou SJ, Li M, Zeng DX, et al. Expression variations of connective tissue growth factor in pulmonary arteries from smokers with and without chronic obstructive pulmonary disease. Sci Rep. 2015;5:8564.
   PubMedGoogle Scholar
• Reimann S, Fink L, Wilhelm J, et al. Increased S100A4 expression in the vasculature of human COPD lungs and murine model of smoke-induced emphysema. Respir Res. 2015;16:127.
   PubMedGoogle Scholar
• Du Y, Ding Y, Chen X, et al. MicroRNA-181c inhibits cigarette smoke-induced chronic obstructive pulmonary disease by regulating CCN1 expression. Respir Res. 2017;18(1):155.
   PubMedGoogle Scholar
• Gu W, Yuan Y, Yang H, et al. Role of miR-195 in cigarette smoke-induced chronic obstructive pulmonary disease. Int Immunopharmacol. 2018;55:49–54.
   PubMed Web of Science ®Google Scholar
• Gu W, Yuan Y, Wang L, et al. Long non-coding RNA TUG1 promotes airway remodelling by suppressing the miR-145-5p/DUSP6 axis in cigarette smoke-induced COPD. J Cell Mol Med. 2019;23(11):7200–7209.
   PubMed Web of Science ®Google Scholar
• Shin JY, Kang ES, Park JH, Cho BO, Jang SI. Anti-inflammatory effect of red ginseng marc, Artemisia scoparia, Paeonia japonica and Angelica gigas extract mixture in LPS-stimulated RAW 264.7 cells. Biomed Rep. 2022;17(1):63.
   PubMedGoogle Scholar
• Gao Y, Chu S, Zhang Z, Chen N. Hepataprotective effects of ginsenoside Rg1 - A review. J Ethnopharmacol. 2017;206:178–183.
   PubMed Web of Science ®Google Scholar
• Kong L, Liu J, Wang J, et al. Icariin inhibits TNF-α/IFN-γ induced inflammatory response via inhibition of the substance P and p38-MAPK signaling pathway in human keratinocytes. Int Immunopharmacol. 2015;29(2):401–407.
   PubMedGoogle Scholar
• Xu C-Q, Liu B-J, Wu J-F, et al. Icariin attenuates LPS-induced acute inflammatory responses: involvement of PI3K/Akt and NF-κB signaling pathway. Eur J Pharmacol. 2010;642(1–3):146–153. doi:10.1016/j.ejphar.2010.05.012
   PubMedGoogle Scholar
• Li W, Zhao R, Wang X, et al. Nobiletin-ameliorated lipopolysaccharide-induced inflammation in acute lung injury by suppression of NF-κB pathway in vivo and vitro. Inflammation. 2018;41(3):996–1007. doi:10.1007/s10753-018-0753-3
   PubMedGoogle Scholar
• Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet commission. Lancet. 2022;400(10356):921–972.
   PubMed Web of Science ®Google Scholar